Equities Analysts Set Expectations for AUPH FY2025 Earnings

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Equities researchers at Leerink Partnrs increased their FY2025 EPS estimates for shares of Aurinia Pharmaceuticals in a research report issued on Tuesday, November 4th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of $0.75 per share for the year, up from their previous forecast of $0.63. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ Q4 2025 earnings at $0.18 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research firms have also recently weighed in on AUPH. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a report on Wednesday. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $10.00 to $21.00 in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.67.

Aurinia Pharmaceuticals Trading Down 3.5%

NASDAQ:AUPH opened at $13.95 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The business’s 50-day simple moving average is $12.22 and its 200-day simple moving average is $10.12. Aurinia Pharmaceuticals has a fifty-two week low of $6.55 and a fifty-two week high of $16.20. The stock has a market capitalization of $1.84 billion, a PE ratio of 32.44 and a beta of 1.30.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AUPH. GAMMA Investing LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 1,744 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Aurinia Pharmaceuticals by 20.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 2,238 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of Aurinia Pharmaceuticals by 27.2% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 13,892 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 2,973 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Aurinia Pharmaceuticals by 32.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 3,191 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Aurinia Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after purchasing an additional 3,497 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.